News
The protein STAT3 helps the immune system to recognise leukemic cells. This interaction, which is important for future immunotherapies, is now understood in detail thanks to a study at the Karl Landsteiner University of Health Sciences (KL Krems). The study showed that STAT3 influences the formation of surface structures on leukemic cells that make them vulnerable to the immune system. If these structures are missing, leukemic cells can escape the body's innate immune surveillance. The expression of STAT3 in and the surface structures on leukemic cells could be a potential biomarker for future immunotherapies.
The KL Department of Water Quality and Health is researching the origin and spread of antibiotic resistance along the Lower Austrian Danube tributaries. The project complements FWF-funded research on the overall situation of the Danube on the same topic.
Does fluorescent marking facilitate the surgical removal of tumors?
Physicians from Karl Landsteiner University of Health Sciences in Krems (KL Krems, Austria) present results of the world's most extensive study headed by the MedUni Vienna investigating the value of 5-aminolevulinic acid in surgery of brain metastases
In the ORF broadcast STUDIO 2, KL psychiatry expert Dr. Beate Schrank today explained the dangers and effects that the (semi-)professional practice of e-sports, i.e. online sports games can have.
The usual disinfectants, such as chlorine or ozone, ensure inactivation of infectious SARS-CoV-2 viruses in bathing water.
Stefan Stieger, Head of the Department of Psychological Methodology at the Department of Psychology and Psychodynamics at KL, was recently appointed to the editorial board of the scientific journal 'Sensors' as Associate Editor. He will serve there for the section 'Wearables'.
How does Austria experience the government measures on the current coronavirus pandemic? How satisfied is the population with the measures taken and what is their personal estimate on the development in the next months?
Doctors at Karl Landsteiner University of Health Sciences review data on immune reactions in heart muscle inflammation. Immunotherapy is a powerful weapon in the fight against cancer, but inflammation of the heart muscle (myocarditis) is one of its most serious side effects. This has been highlighted in a review article on the immunological causes and processes of myocarditis, which has just been published by an international research team. Autoimmune reactions are in fact among the most common causes of myocarditis. And such reactions can be triggered by cancer immunotherapies due to their specific modes of action. The increasing use of these treatments could therefore lead to an increase in cases of myocarditis.
The comparison of the bone structure of two early human finds in South Africa suggests, according to a study involving KL researchers, that the development from tree to terrestrial form of living and thus climbing to walking upright in early humans may not have been linear. This was demonstrated in a recently published study using the worldwide unique software to examine bone structure and density, developed by Professor Dieter Pahr, researcher at KL Krems and TU Vienna.
Since Tuesday evening, the online platform www.kl.ac.at/coronavirus has been offering secure, up-to-date and well-founded recommendations for action for doctors in private practice. These recommendations are made available by doctors for doctors after prior review, analysis and daily updates. The new information platform recorded more than 15,000 hits in the first 24 hours.
Researchers from the Karl Landsteiner University aim to develop a novel model of bone metastatic disease in breast cancer. A new project just launched aims at gaining insights into the development of bone metastases in breast cancer patients and identifying biomarkers as well as new treatment strategies.
Major worldwide research project discovers that 71% of women are unhappy with their breast size. The resulting reduced breast awareness might influence cancer detection by self-examination.
A novel agent called Selinexor has opened up new options for the treatment of patients with refractory myeloma. This was the conclusion of a major international clinical trial in which also the Karl Landsteiner University of Health Sciences in Krems, Austria (KL Krems) participated. The results have now been published in the New England Journal of Medicine. Thanks to a new mode of action, the compound brings hope to the growing number of patients whose tumor cells have become resistant to the three backbone drug classes.